Department of Obstetrics and Gynecology, Monmouth Medical Center, Long Branch, NJ (Biswas).
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA (Toro).
Am J Obstet Gynecol MFM. 2024 Oct;6(10):101459. doi: 10.1016/j.ajogmf.2024.101459. Epub 2024 Aug 6.
To assess the effect of propranolol on time to delivery among patients undergoing induction or augmentation of labor.
PubMed, Scopus, Cochrane Library, ClinicalTrials.gov, and CINAHL (EBSCO) were searched from inception to December 2023.
Randomized controlled trials (RCTs) that examined the impact of propranolol on time to delivery among patients undergoing induction or augmentation of labor were included. RCTs that included stillbirth before randomization, non-randomized trials, observational, cohort, case control, or studies in which the control group included an intervention other than standard care were excluded.
Primary outcome was time to delivery after administration of propranolol among patients undergoing induction or augmentation of labor. The summary measures were reported as summary mean difference (MD) or relative risk with 95% confidence interval (CI).
Nine RCTs including 1,182 patients were included in this meta-analysis. Five studies investigated the effect of propranolol among patients undergoing induction of labor (IOL) and demonstrated a significant decrease in time to delivery (MD, -91.5 minutes, 95% CI -110.6 to -72.4). Four studies investigated the effect of propranolol among patients undergoing augmentation of labor and showed no significant decrease in time to delivery (MD, -2.98 minutes, 95% CI -21.6 to 15.6). Our pooled analysis demonstrated that the use of propranolol in IOL and augmentation was associated with a decrease in time to delivery from administration of propranolol compared to placebo (mean difference, -46.15 minutes, 95% CI -59.48 to -32.81). The meta-analysis found no increased risk of PPH, blood transfusion, cesarean delivery rates, or NICU admission with the use of propranolol during labor.
The use of propranolol during induction of labor shortens overall time to delivery by about 91 minutes and did not significantly decrease time to delivery in those undergoing augmentation of labor.
评估普萘洛尔对引产或催产患者分娩时间的影响。
从建库至 2023 年 12 月,检索了 PubMed、Scopus、Cochrane 图书馆、ClinicalTrials.gov 和 CINAHL(EBSCO)。
纳入研究普萘洛尔对引产或催产患者分娩时间影响的随机对照试验(RCT)。排除在随机分组前发生死产的 RCT、非随机试验、观察性研究、队列研究、病例对照研究,或对照组接受除标准护理以外的干预措施的研究。
主要结局是接受引产或催产的患者使用普萘洛尔后分娩时间。汇总指标以汇总均数差值(MD)或 95%置信区间(CI)表示的相对风险报告。
纳入本 meta 分析的 9 项 RCT 共纳入 1182 例患者。5 项研究评估了普萘洛尔对引产患者的影响,结果显示分娩时间显著缩短(MD,-91.5 分钟,95%CI -110.6 至 -72.4)。4 项研究评估了普萘洛尔对催产患者的影响,结果显示分娩时间无显著缩短(MD,-2.98 分钟,95%CI -21.6 至 15.6)。汇总分析显示,与安慰剂相比,引产和催产时使用普萘洛尔与分娩时间从给药开始缩短有关(均数差,-46.15 分钟,95%CI -59.48 至 -32.81)。meta 分析发现,使用普萘洛尔不会增加产后出血、输血、剖宫产率或新生儿重症监护病房入住率。
在引产时使用普萘洛尔可使总分娩时间缩短约 91 分钟,但在催产时不会显著缩短分娩时间。